Remarkably, we consistently found robust associations between high numbers of tumor-infiltrating CD8+, PD-1+, and/or CD8+PD-1+ immune cells and superior patient survival across cancer types, despite the heterogeneity in tissues, cancers, patient stage, and therapies. The gene discussed is CD8A; the disease is neoplasm.